| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | Lovastatin |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/A, D/P, T/T, , MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 75330-75-5 | MF: | C24H36O5 |
|---|---|---|---|
| MW: | 404.54 | Specification: | ≥99% |
| Appearance: | White Powder | EINECS: | 616-212-7 |
| High Light: | API Active Pharmaceutical Ingredient,Human API Pharma Ingredients |
||
High Purity Chemical Lovastatin Powder CAS 75330-75-5
| Production name | Lovastatin |
| MOQ | 1KG |
| CAS No. | 75330-75-5 |
| Appearance | White powder |
| Molecular Formula | 75330-75-5 |
| Molecular Weight | 404.540 |
| Assay | 99% |
The Introduction of Lovastatin :
Lovastatin is a hexahydronaphthyl ester isolated from Aspergillus terreus cultures, an inactive lactone, which is active only after being hydrolyzed after oral administration, and has a strong competitive inhibitory effect on HMG-CoA reductase in the liver. HMG-CoA reductase is the rate-limiting enzyme for ab initio cholesterol synthesis in vivo, and inhibition of this enzyme blocks the conversion of HMG-CoA to methyl valeric acid, resulting in a significant decrease in cholesterol synthesis and causing enhanced expression of hepatic LDL receptors, resulting in enhanced clearance of plasma LDL-C. The reduction in cholesterol synthesis also leads to a reduction in hepatic synthesis of ApoB100 and thus VLDL synthesis. Clinical observation shows that this product has good effect on lowering plasma total cholesterol and LDLC regardless of the various causes of hypercholesterolemia such as heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia, diabetes mellitus or nephrotic syndrome.
The Application & Function of Lovastatin :
1. Lovastatin for cardiovascular system drugs to stop the development of atherosclerosis and reduce the risk of myocardial infarction, etc.
2. Cholesterol-lowering drug and competitive inhibitor of HMG-CoA reductase, a rate-limiting enzyme for cholesterol synthesis. Blocks the production of mevalonate, a key compound for cholesterol and isoprene production. This product is a substrate for Pgp and CYP3A. It increases cellular resistance to anti-cancer drugs, such as adriamycin, and induces apoptosis in myeloma cells. The product induces apoptosis in numerous cancer cells, in part by inhibiting Rho family GTPases. It causes the cell cycle to be captured in the G1 and G2/M phases.